Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Essen Biotech
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06640582CT.gov TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas | — | Recruiting | — | — | — |
NCT04964960CT.gov Pembro+Chemo in Brain Mets | — | Terminated | — | — | — |
NCT02798406CT.gov Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Essen Biotech | P2 | B · 60 |
| Irinotecan | University of California, Davis | P2 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Sorafenib | Virginia Commonwealth University | P2 | BB |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | BB |
| Capecitabine | Northwell Health | P2 | B |
| Carboplatin | John L. Villano, MD, PhD | P3 | B |
| Vorinostat | Duke University | P2 | B |
+42 more in the Brain Cancer cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Brain Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-brain-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →